HIV

News

Gilead plans European trial of twice-yearly HIV PrEP drug

Gilead Sciences has said it will soon start a clinical trial in Europe of its twice-yearly HIV injection Sunlenca for pre-exposure prophylaxis (PrEP), a potential successo

News

ViiV’s injectable HIV PrEP drug Apretude gets EU okay

People in the EU who need access to pre-exposure prophylaxis (PrEP) for HIV could soon have a new option with fewer doses after the European Commission approved ViiV Healt

Sales & Marketing

All eyes remain on US government patent dispute with Gilead

A high-stakes court battle is currently being fought in the US, with the government accusing a big pharma company of patent infringement for the first time.

News

Switch study says patients prefer ViiV’s injectable HIV drug

When ViiV Healthcare and Johnson & Johnson launched their once-monthly injectable HIV treatment Cabenuva in 2021, they predicted that patients would prefer that option

News

Gilead, Teva cleared in $3.6bn ‘pay-for-delay’ trial

The jury in a California court has sided with Gilead Sciences and Teva in a lawsuit that accused the drugmakers of conspiring to delay the launch of generic versions of th

News